KFF Health News chief Washington correspondent Julie Rovner discussed the Department of Health and Human Services, the federal workforce, and Robert F. Kennedy Jr. on WAMU’s “1A” on Jan. 8. Click here to hear Rovner on “1A” KFF Health News video producer and visual reporter Hannah Norman discussed PFAS contamination in well water on KVPR’s…
Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…
Finding missing health insurance is critical to keeping revenue cycles on track. Insurance eligibility verification is an important process providers use to confirm active coverage, including additional coverage a patient may have forgotten. According to Experian Health’s State of Claims 2024 survey, almost a fifth of providers say missing coverage is a top reason for…
A BioMarin Pharmaceutical drug met just one of two main goals of a Phase 3 test in a rare inherited enzyme deficiency with no FDA-approved therapies. The drug, a fusion protein, came from BioMarin’s 2025 acquisition of Inozyme Pharma. The post BioMarin’s Mixed Bag of Phase 3 Data Dim Prospects for Rare Disease Drug appeared…
Six healthcare startups using AI to address a variety of healthcare challenges will vie for the top prize at the conference at Pegasus Park in Dallas on September 18. Register today! The post A Preview of Healthcare Startups Competing in the INVEST Digital Health Pitch Perfect Contest appeared first on MedCity News.
Bristol Myers Squibb’s Cobenfy treats schizophrenia by going after a different target than currently available antipsychotic drugs, which is intended to offer better efficacy and safety. The drug came from the pharma giant’s $14 billion acquisition of Karuna Therapeutics. The post FDA Approval of Bristol Myers Drug Makes It the First Novel Schizophrenia Med in…
Healthcare leaders who shape that future need more than innovation. They need a visible, credible voice that helps the people around them — patients, clinicians, employees, partners, and investors — understand what the change is, why it matters, and why this is the right person to lead it. The post The Healthcare Leaders Driving Change…
Several healthcare provisions, including drug reforms, were left out of the government funding bill, angering some healthcare leaders. The post Healthcare Leaders Slam Exclusion of Key Healthcare Provisions in Spending Package appeared first on MedCity News.
These products have yet to offer treatment solutions designed to get users from their current health state to a desired future health state. This creates a massive, untapped opening for tools that move people from awareness to action in a clinically meaningful way, without the cost and access barriers of engaging the healthcare system or requiring…
Hospitals’ flat revenues are clashing with rising costs and excessive reimbursement denials from payers, said Rod Hanners, CEO of Keck Medicine of USC. He warned that policy efforts focused solely on limiting provider payments ignore the larger issue of unchecked profits among payers, drugmakers and other healthcare industry players. The post Why Hospitals Are Losing…